##  [Enabling Successful BLA Sample Testing and Regulatory Operations in China for a Swiss Biologics Company](/index%2ephp/success-stories/enabling-successful-bla-sample-testing-and-regulatory-operations-in-china-for-a-swiss-biologics-company) 

# Enabling Successful BLA Sample Testing and Regulatory Operations in China for a Swiss Biologics Company

Delivering comprehensive China Regulatory Affairs support, BLA sample testing coordination, NMPA Regulatory operations, and biologics submission support for a monoclonal antibody product while ensuring compliance with China's National Medical Products Administration (NMPA) requirements and accelerating the Biologics License Application (BLA) review process.





![]()









### End-to-end



Regulatory operations support aligned with NMPA requirements







### Timely



coordination of sample testing and dossier submission activities







### Proactive



risk mitigation to prevent Regulatory delays













![Client Overview]()



![Icon]()  

## Client Overview



A Switzerland-based biopharmaceutical company required Regulatory Affairs and Regulatory Operations support in China for a monoclonal antibody product undergoing the Biologics License Application (BLA) process. The client sought expert assistance in coordinating sample testing, dossier preparation, Regulatory communications, and submission activities while ensuring compliance with evolving China NMPA regulations and biologics registration requirements.











![Background Icon]()  

## Background



As part of its China market access strategy, the client needed to complete sample testing and Regulatory documentation activities to support a BLA submission for a monoclonal antibody product. The process involved coordination with multiple stakeholders, alignment with NMPA technical requirements, and strict adherence to Regulatory timelines.

Given the complexity of China's biologics Regulatory framework and evolving NMPA expectations, the client required a trusted Regulatory partner capable of managing sample testing logistics, dossier readiness, Regulatory communications, and submission support to facilitate a smooth review process.





![Scope Icon]()  

## Services in Scope



![]()

BLA Sample Testing Coordination and Support



![]()

Regulatory Operations Management



![]()

Dossier Preparation and Submission Support



![]()

Sample Importation and Delivery to NMPA Test Centers



![]()

NMPA Communication and Query Management



![]()

Test Method Alignment and Risk Assessment



![]()

Regulatory Documentation Review and Compliance Support



![]()

Stakeholder Coordination Across Global Teams Tracking















![Challenge]()



![Challenge]()

## Challenge



![Challenge]()

**Tight Regulatory Timelines** The client faced aggressive timelines for completing sample testing and Regulatory documentation activities required for BLA submission.





![Challenge]()

**Evolving NMPA Requirements** China's evolving Regulatory landscape required close monitoring of NMPA expectations and alignment with current biologics registration requirements.





![Challenge]()

**Sample and Test Method Alignment** Ensuring that testing methodologies met NMPA expectations was critical to avoiding delays and minimizing Regulatory risk.





![Challenge]()

**Complex Stakeholder Coordination** Managing communication among global stakeholders, test centers, and Health Authorities required strong Regulatory project management and operational oversight.















![Challenge]()

## Solution



1

![Challenge]()

##### Sample Testing Coordination

Coordinated test sample preparation, logistics, and delivery to the designated NMPA testing center while ensuring compliance with local requirements.





2

![Challenge]()

##### Regulatory Documentation Support

Supported dossier preparation and documentation activities aligned with NMPA submission expectations and biologics Regulatory requirements.





3

![Challenge]()

##### NMPA Communication Management

Provided end-to-end query management and communication support with the NMPA testing center to ensure timely issue resolution and project continuity.





4

![Challenge]()

##### Risk Identification and Mitigation

Proactively identified potential Regulatory and technical risks and aligned testing methods with NMPA expectations to prevent delays during the review process.





5

![Challenge]()

##### Cross-Functional Stakeholder Coordination

Facilitated collaboration among global stakeholders to ensure the timely execution of testing, documentation, and Regulatory operations activities.











![Challenge]()

## Impact



Freyr's support enabled the client to successfully complete critical sample testing and Regulatory operations activities required for the BLA review process in China.



![Challenge]()

##### Regulatory Excellence 

- Ensured alignment with NMPA technical and Regulatory requirements
- Supported compliant execution of biologics testing activities
- Strengthened Regulatory Readiness for BLA review
- Improved submission quality and documentation alignment





![Challenge]()

##### Faster Submission Execution 

- Completed sample testing activities within project timelines
- Accelerated coordination between stakeholders and NMPA testing centers
- Reduced risks associated with Regulatory non-alignment





![Challenge]()

##### Operational Efficiency 

- Streamlined sample importation, testing, and documentation workflows
- Improved communication and issue-resolution processes
- Enhanced Regulatory project management and oversight





![Challenge]()

##### Business Value 

- Minimized potential delays in the BLA review process
- Supported the successful progression of the biologic’s registration pathway
- Strengthened the client's China market access strategy
- Optimized Regulatory operations for biologics development in China